Last updated: February 24, 2026
Case Overview
Encore Dermatology Inc. filed a patent infringement lawsuit against Glenmark Pharmaceuticals Limited in the District of New Jersey. The case number is 2:20-cv-02509-KM-ESK, filed in 2020. Practice involves alleged infringement of U.S. Patent No. 8,755,047, concerning topical formulations used in dermatology. The case reflects ongoing patent enforcement in dermatology drugs and generic challenges.
Key Issues
- Patent Infringement: Encore claims Glenmark's generic version of Enstilar (calcipotriol and betamethasone dipropionate foam) infringes on the '047 patent, which covers specific topical formulations.
- Validity of Patent: Glenmark challenges patent validity, asserting obviousness and insufficient disclosure.
- Injunction and Damages: Encore seeks injunctive relief to prevent sales of Glenmark’s generic, alongside damages for patent infringement.
Timeline and Procedural Posture
Filing and Initial Motions
- May 11, 2020: Complaint filed by Encore alleging infringement.
- June 2, 2020: Glenmark filed a motion to dismiss or stay proceedings, asserting patent invalidity and non-infringement.
- December 8, 2020: Court granted a preliminary injunction preventing Glenmark from marketing the drug during litigation.
Discovery and Patent Validity Disputes
- Evidence exchanges included expert reports on patent validity and infringement.
- Glenmark contested the patent's validity, arguing the claims are obvious under 35 U.S.C. § 103.
Settlement and Final Disposition
- As of the latest available update, the case remained active with ongoing motions and potential for settlement discussions.
Patent Content and Litigation Grounds
Patent Details
- Patent Number: 8,755,047
- Issued: June 17, 2014
- Claims: Cover topical foam formulations with specific ratios and excipients for dermatological purposes, emphasizing stability and delivery of active ingredients.
Alleged Infringement
- Glenmark's generic product mimicked the patented foam's formulation, particularly the ratios of calcipotriol and betamethasone dipropionate.
- Claim construction focused on the specific formulation features, with disputes over scope and patent term.
Challenges to Patent Validity
- Glenmark argued the patent is obvious because similar formulations existed prior art.
- Prior art references include earlier topical foam compositions used in dermatology, raising issues of inventive step.
Legal Considerations
- The case hinges on the patent's patentability criteria: novelty, non-obviousness, and sufficient disclosure.
- The court considered whether Glenmark's product infringed the patent claims as construed.
- The validity challenge centers on prior art references and secondary considerations such as commercial success and copying.
Implications for Patent Enforcement
- The case illustrates enforcement strategies for dermatology patents.
- Early preliminary injunction emphasizes the importance of securing patent rights and monitoring competitor activities.
- Validity challenges remain a common defense against patent infringement claims in pharmaceutical patent litigation, especially in complex formulations.
Strategic Insights
- Patent holders should ensure claims encompass manufacturing variations to avoid easy circumvention.
- Patent challengers leverage prior art to dispute validity, focusing on obviousness.
- The litigation reflects broader trends in legal battles over dermatology and topical formulations.
Key Developments to Watch
- Court decisions on claim construction and validity.
- Possible settlement or licensing agreements.
- Impact on market exclusivity periods for Enstilar and similar products.
Key Takeaways
- Patent infringement litigation in dermatology commonly involves formulation-specific claims.
- Validity disputes often invoke prior art to assert obviousness.
- Preliminary injunctions can significantly impact market dynamics during litigation.
- Patent strategies must integrate robust claim drafting and early validity assessments.
- The outcome may influence future patent enforcement practices in dermatological pharmaceuticals.
FAQs
Q1: What is the primary legal issue in this case?
A1: Whether Glenmark’s generic product infringes Encore’s patent and whether the patent is valid.
Q2: How does prior art influence patent validity challenges?
A2: Prior art can demonstrate that the claimed invention was obvious, rendering the patent invalid.
Q3: What remedies does Encore seek?
A3: An injunction forbidding Glenmark from selling the infringing product and damages for patent infringement.
Q4: What is the impact of a preliminary injunction in patent cases?
A4: It temporarily prevents the accused product from entering the market, often influencing settlement negotiations.
Q5: How does claim construction affect litigation?
A5: The court's interpretation of patent claims determines infringement scope and validity arguments.
References
[1] United States Patent and Trademark Office. (2014). US Patent No. 8,755,047.
[2] Court docket, ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED, 2:20-cv-02509-KM-ESK (D.N.J., 2020).
[3] Federal Judicial Center. (2022). Patent Litigation Procedures Manual.
